SUZHOU, China – August 22, 2019 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, today announced the opening of their new GMP facilities in Kunming, China. Located within Yunnan Boya Private Hospital, the facilities comprise over 600 square meters, with over 200 square meters of dedicated space built and managed according to both U.S. and China GMP standards.

“We are very pleased to continue to add to our manufacturing and banking capabilities,” commented Benno Jiao, CEO of the Company. “This is a key milestone to support our various stem-cell and oncology product lines and clinical studies, as it expands our research and development space, as well as our access to patients across China who are suffering from unmet medical needs.”

The Company currently operates clinics and research and development labs in Suzhou, Shenzhen, Beijing, Kunming and Ganzhou, with further locations planned for Chongqing, Wuhan, and other cities across China.

Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as “will,” “may,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.

Contact:

Re-Stem Biotech

judyanna.chen@restembiotech.com